Programmed death-ligand 1 (PD-L1) inhibitors, such as atezolizumab (Tecentriq and Tecentriq Hybreza), avelumab (Bavencio), and durvalumab (Imfinzi), target the PD-L1 protein on cancer cells to disrupt immune suppression. Here, CD274 is linked to cancer.